Phase 1a Clinical Trial of XRD-0394, a First-in-Class Dual Ataxia-Telangiectasia Mutated and DNA-Dependent Protein Kinase Inhibitor, in Combination With Palliative Radiation Therapy.
Journal: International journal of radiation oncology, biology, physics
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Chen CT, Gensheimer MF, Gilmer TM, et al. (2026). "Phase 1a Clinical Trial of XRD-0394, a First-in-Class Dual Ataxia-Telangiectasia Mutated and DNA-Dependent Protein Kinase Inhibitor, in Combination With Palliative Radiation Therapy.". International journal of radiation oncology, biology, physics. https://doi.org/10.1016/j.ijrobp.2026.08.069